A variety of chemical compounds serve as inhibitors to Olfr315, interacting with different components of the receptor's signaling process to decrease its operational effectiveness. Some molecules imitate the receptor's natural ligands, attaching to its active site and initiating a desensitization response, which diminishes the receptor's capacity to perceive subsequent signals. Other compounds exert their influence on the receptor's downstream signaling, one by impeding an enzyme involved in the production of a key signaling molecule, and another by modifying the receptor's structure. There is also antagonism displayed by compounds that block essential calcium channels for signal transmission, as well as those that affect Olfr315 by altering the larger network of olfactory signaling. Furthermore, some agents, not primarily designed to interact with olfactory receptors, may still inadvertently suppress the activity of Olfr315.
Additionally, the context in which the olfactory receptor operates can significantly impact the regulation of Olfr315. Certain antagonists that target related receptors can reduce Olfr315's sensitivity by changing the surrounding neuronal environment. There are agents that disrupt standard signaling by binding to proteins that interact with the receptor, potentially restraining Olfr315's normal communications. Other substances may influence the receptor's functionality by affecting the metabolic processing of odorants, thus impacting the availability of ligands. Moreover, some compounds indirectly influence Olfr315 by engaging with neighboring signaling mechanisms related to different receptors, which may lead to variations in key signaling molecules and changes in the neuronal membrane's properties, consequently affecting the signaling processes of Olfr315.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Icilin | 36945-98-9 | sc-201557 sc-201557A | 10 mg 50 mg | $91.00 $257.00 | 9 | |
Agonist at TRPM8, the activation of which can cause a decrease in the sensitivity of Olfr315 due to competitive signal modulation in olfactory sensory neurons. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Blocks the signaling pathways downstream of G-protein coupled receptors like Olfr315 via inhibition of adenylate cyclase, leading to reduced cyclic AMP levels and receptor desensitization. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Non-selective inhibitor of G-protein coupled receptors which may interfere with the signaling pathways of Olfr315 by altering receptor conformation and function. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $188.00 $250.00 | 13 | |
Blocks calcium channels that are indirectly linked to Olfr315 function; reduced intracellular calcium can inhibit receptor activation and downstream signaling. | ||||||
Capsazepine | 138977-28-3 | sc-201098 sc-201098A | 5 mg 25 mg | $148.00 $459.00 | 11 | |
Antagonist of the vanilloid receptor, which may indirectly decrease the sensitivity and activity of adjacent receptors like Olfr315 by altering the olfactory neuron environment. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Alters G-protein coupled receptor function by binding to G proteins, potentially inhibiting Olfr315 signaling through its interference with G-protein activation. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Inhibits cytochrome P450 enzymes which are involved in the clearance and metabolism of odorants, potentially influencing Olfr315 activity by altering ligand availability. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $92.00 $356.00 | 1 | |
Adenosine A2A receptor antagonist that could indirectly affect Olfr315 activity by modulating cAMP levels in the olfactory signal transduction pathways. | ||||||
Rimonabant | 168273-06-1 | sc-205491 sc-205491A | 5 mg 10 mg | $73.00 $163.00 | 15 | |
Cannabinoid receptor antagonist which could indirectly inhibit Olfr315 by altering the lipid raft composition of neuronal membranes, affecting receptor function and signaling. | ||||||